Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

NCT03382574 · clinicaltrials.gov ↗
EARLY_PHASE1
Phase
TERMINATED
Status
2
Enrollment
NIH
Sponsor class

Stopped it was decided that due to lack of accrual on the trial, and low potential for accruing over the near future, the trial will be shut down.

Conditions

Interventions

Sponsor

National Cancer Institute (NCI)